Financial News Search | Sharemaestro Newsreel

08:00 3 Aug 2026

Mexico Business News Deals and strategy Main company 🇲🇽 Mexico

AstraZeneca, Bristol Myers Squibb Explore US$400 Billion Merger

The merger would be one of the biggest pharma deals ever. AstraZeneca’s market capitalization stood at $264 billion as of Friday’s close, while Bristol Myers Squibb had a total valuation of $133 billion. Continue Reading

AZN1N main company

Sharemaestro market context Price below Trend Line 52 weeks -10.0% · Next-week setup negative 16.9%

08:00 3 Aug 2026

Pharmaceutical Technology Deals and strategy Main company 🇲🇽 Mexico

AstraZeneca shares slump after $400bn BMS merger rumours

Shares in AstraZeneca dropped by nearly 3% at market open after a report that the drugmaker is in talks with oncology rival Bristol Myers Squibb (BMS) regarding a mega-merger deal. According to the Financial Times (FT), which first reported the discussions, a tie-up would …

AZN1N main company

Sharemaestro market context Price below Trend Line 52 weeks -10.0% · Next-week setup negative 16.9%

07:01 3 Aug 2026

nasdaq.com Earnings Main company 🇲🇽 Mexico

AstraZeneca And Bristol Myers Reportedly In Talks On $400 Bln Deal

(RTTNews) - AstraZeneca Plc (AZN) and Bristol Myers Squibb (BMY) are in talks over a $400 billion deal to combine the companies, Financial Times reported. Neither company has disclosed any details of the merger, and deal closure timelines are unclear. Both AstraZeneca and Bristol …

AZN1N main company

Sharemaestro market context Price below Trend Line 52 weeks -10.0% · Next-week setup negative 16.9%

22:14 2 Aug 2026

finance.yahoo.com Deals and strategy Main company 🇲🇽 Mexico

AstraZeneca and Bristol-Myers Squibb in talks over potential merger - Report

Investing.com -- AstraZeneca PLC (NYSE:AZN) and Bristol-Myers Squibb Company (NYSE:BMY) have held talks in recent months about a deal that would combine the companies into one, according to a Financial Times report. A combined entity would carry a value of nearly $400 billion, which …

AZN1N main company

Sharemaestro market context Price below Trend Line 52 weeks -10.0% · Next-week setup negative 16.9%

21:20 2 Aug 2026

finance.yahoo.com Deals and strategy Main company 🇲🇽 Mexico

AstraZeneca plots £300bn tie-up with US rival

AstraZeneca is plotting a $400bn (£300bn) merger with US rival Bristol Myers Squibb in a deal likely to raise fresh questions over the company's ties to the UK. Britain's second-most valuable company has held talks with Bristol Myers Squibb in recent months about a …

AZN1N main company

Sharemaestro market context Price below Trend Line 52 weeks -10.0% · Next-week setup negative 16.9%

20:23 2 Aug 2026

seekingalpha.com Deals and strategy Main company 🇲🇽 Mexico

AstraZeneca, Bristol Myers held merger talks, Financial Times reports

Drew Angerer/Getty Images News AstraZeneca (AZN [https://seekingalpha.com/symbol/AZN]) and Bristol Myers Squibb (BMY [https://seekingalpha.com/symbol/BMY]) have held preliminary discussions about a potential combination that would create one of the world's largest pharmaceutical companies, according to a report by the Financial Times. For investors, a deal would …

AZN1N main company

Sharemaestro market context Price below Trend Line 52 weeks -10.0% · Next-week setup negative 16.9%

07:30 31 Jul 2026

finance.yahoo.com Earnings Main company 🇲🇽 Mexico

Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy

Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca's Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU …

AZN1N main company

Sharemaestro market context Price below Trend Line 52 weeks -10.0% · Next-week setup negative 16.9%

12:09 29 Jul 2026

finance.yahoo.com Earnings Main company 🇲🇽 Mexico

AstraZeneca (LSE:AZN) Stock In Focus After Sone Ve Win And Mixed Ultomiris Data

Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. AstraZeneca reported positive Phase III results for sonesitatug vedotin in Claudin 18.2-positive advanced gastric …

AZN1N main company

Sharemaestro market context Price below Trend Line 52 weeks -10.0% · Next-week setup negative 16.9%

08:09 29 Jul 2026

finance.yahoo.com Earnings Main company 🇲🇽 Mexico

Does AstraZeneca (LSE:AZN) Have More Value Than The Market Prices In?

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. AstraZeneca stock has delivered a 73.3% total return over the past five years, and both the intrinsic value estimate using a Discounted Cash Flow (DCF) approach and …

AZN1N main company

Sharemaestro market context Price below Trend Line 52 weeks -10.0% · Next-week setup negative 16.9%

18:41 28 Jul 2026

finance.yahoo.com Earnings Main company 🇲🇽 Mexico

AstraZeneca Cancer Drug Targets Up to $5 Billion in Sales

This article first appeared on GuruFocus. AstraZeneca (NYSE:AZN), a global pharmaceutical company focused on oncology and other major therapeutic areas, could gain a potential new cancer treatment with estimated peak sales between $3 billion and $5 billion after a late-stage study produced positive topline …

AZN1N main company

Sharemaestro market context Price below Trend Line 52 weeks -10.0% · Next-week setup negative 16.9%

14:32 28 Jul 2026

finance.yahoo.com Analyst action Main company 🇲🇽 Mexico

AstraZeneca's drug pipeine is splitting opinion among City analysts

AstraZeneca's drug pipeine is splitting opinion among City analysts Proactive uses images sourced from Shutterstock AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) drug pipeline is splitting opinion among City brokers, with Citibank upgrading its price target to 17,800p whilst analysts at Deutsche Bank repeated a 'sell' rating …

AZN1N main company

Sharemaestro market context Price below Trend Line 52 weeks -10.0% · Next-week setup negative 16.9%

10:13 28 Jul 2026

finance.yahoo.com Earnings Main company 🇲🇽 Mexico

The Zacks Analyst Blog Highlights Apple, Microsoft, Amazon, LVMH, AstraZeneca, Shell, Airbus and UBS

For Immediate Release Chicago, IL – July 28, 2026 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in …

AZN1N main company

Sharemaestro market context Price below Trend Line 52 weeks -10.0% · Next-week setup negative 16.9%

20:16 27 Jul 2026

finance.yahoo.com Earnings Main company 🇲🇽 Mexico

AstraZeneca's $2.63 Earnings Beat Supports $80 Billion Revenue Target

This article first appeared on GuruFocus. AstraZeneca (NYSE:AZN), a global pharmaceutical company focused on medicines including cancer and rare-disease treatments, maintained its 2026 and 2030 forecasts after second-quarter core earnings exceeded market expectations, helping ease some investor concern following recent clinical-trial setbacks. Core earnings …

AZN1N main company

Sharemaestro market context Price below Trend Line 52 weeks -10.0% · Next-week setup negative 16.9%

20:00 27 Jul 2026

finance.yahoo.com Earnings Main company 🇲🇽 Mexico

AstraZeneca PLC (AZN) Q2 2026 Earnings Call Highlights: Strong Oncology and Rare Disease Growth ...

This article first appeared on GuruFocus. Total Revenue Growth: 6% increase in the first half of 2026. Product Revenue Growth: 6% increase in the first half of 2026. Alliance Revenue Growth: 29% increase, driven by higher profit shares from partnered medicines. Core Gross Margin: …

AZN1N main company

Sharemaestro market context Price below Trend Line 52 weeks -10.0% · Next-week setup negative 16.9%

18:54 27 Jul 2026

finance.yahoo.com Earnings Main company 🇲🇽 Mexico

AZN Q2 Earnings and Sales Beat, Key Drugs Offset Generic Pressure

AstraZeneca AZN reported second-quarter 2026 core earnings of $2.63 per share, which beat the Zacks Consensus Estimate of $2.50. Earnings rose 21% year over year on a reported basis and 18% at constant exchange rate (CER). Total revenues of $15.38 billion rose 6% on …

AZN1N main company

Sharemaestro market context Price below Trend Line 52 weeks -10.0% · Next-week setup negative 16.9%

17:03 27 Jul 2026

seekingalpha.com Market update Main company 🇲🇽 Mexico

Omeros gains as AstraZeneca's Ultomiris fails in rare blood disorder

[blood cells] cosmin4000/iStock via Getty Images * The failure of a phase 3 trial of AstraZeneca's (AZN [https://seekingalpha.com/symbol/AZN]) Ultomiris (ravulizumab) phase to treat transplant-associated thrombotic microangiopathy, a rare disorder leading to blood clots and harm to small blood vessels, has led shares of Omeros …

AZN1N main company

Sharemaestro market context Price below Trend Line 52 weeks -10.0% · Next-week setup negative 16.9%

16:58 27 Jul 2026

finance.yahoo.com Earnings Main company 🇲🇽 Mexico

Astrazeneca (AZN) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates

Astrazeneca (AZN) reported $15.38 billion in revenue for the quarter ended June 2026, representing a year-over-year increase of 6.4%. EPS of $2.63 for the same period compares to $2.18 a year ago. The reported revenue represents a surprise of +0.48% over the Zacks Consensus …

AZN1N main company

Sharemaestro market context Price below Trend Line 52 weeks -10.0% · Next-week setup negative 16.9%

12:56 27 Jul 2026

finance.yahoo.com Earnings Main company 🇲🇽 Mexico

AstraZeneca Q2 2026 earnings beat on cancer drug sales

AstraZeneca reported second-quarter results on Monday that topped profit expectations, with the Anglo-Swedish pharmaceutical company holding its 2026 guidance and $80 billion annual revenue target for 2030. Core earnings per share reached $2.63 for the three months ended June 30, a gain of 18% …

AZN1N main company

Sharemaestro market context Price below Trend Line 52 weeks -10.0% · Next-week setup negative 16.9%

12:52 27 Jul 2026

finance.yahoo.com Earnings Main company 🇲🇽 Mexico

Earnings live: LVMH sales grow as US luxury shoppers boost results

Earnings season kicks into high gear this week. AstraZeneca (AZN) and Nucor (NUE) report on Monday, with results from SK Hynix (SKHY), Visa (V), Coca-Cola (KO), Boeing (BA), Ford (F), ExxonMobil (XOM), and Chevron (CVX) coming later in the week. The main focus, though, …

AZN1N main company

Sharemaestro market context Price below Trend Line 52 weeks -10.0% · Next-week setup negative 16.9%

12:52 27 Jul 2026

finance.yahoo.com Earnings Main company 🇲🇽 Mexico

Earnings live: AstraZeneca stock rises to kick off a busy earnings week

Earnings season kicks into high gear this week. AstraZeneca (AZN) and Nucor (NUE) report on Monday, with results from SK Hynix (SKHY), Visa (V), Coca-Cola (KO), Boeing (BA), Ford (F), ExxonMobil (XOM), and Chevron (CVX) coming later in the week. The main focus, though, …

AZN1N main company

Sharemaestro market context Price below Trend Line 52 weeks -10.0% · Next-week setup negative 16.9%

12:29 27 Jul 2026

finance.yahoo.com Earnings Main company 🇲🇽 Mexico

AstraZeneca profit rises on strong cancer drug sales

AstraZeneca reconfirmed its outlook for the full year (Hector RETAMAL) British pharmaceutical giant AstraZeneca on Monday said net profit rose in the second quarter, driven once again by strong growth in sales of its cancer drugs. Profit after tax climbed more than two percent …

AZN1N main company

Sharemaestro market context Price below Trend Line 52 weeks -10.0% · Next-week setup negative 16.9%

12:05 27 Jul 2026

finance.yahoo.com Earnings Main company 🇲🇽 Mexico

Sonesitatug vedotin demonstrated a statistically significant and highly clinically meaningful improvement in overall survival in 2nd and later-line CLDN18.2-positive advanced gastric/GEJ cancers

Results provide opportunity to expand CLDN18.2 positivity to ≥25% expression, representing approximately 60% of patients in this setting CLARITY-Gastric01 is the first Phase III trial to show overall survival benefit with an anti-CLDN18.2 ADC in this setting First pivotal readout from AstraZeneca's wholly owned …

AZN1N main company

Sharemaestro market context Price below Trend Line 52 weeks -10.0% · Next-week setup negative 16.9%

12:00 27 Jul 2026

finance.yahoo.com Earnings Main company 🇲🇽 Mexico

AstraZeneca results: H1 and Q2 2026

Growth momentum continues. On track to deliver ambition of $80 billion in Total Revenue in 2030 CAMBRIDGE, England, July 27, 2026--(BUSINESS WIRE)--AstraZeneca: Revenue and EPS summary H1 2026 % Change Q2 2026 % Change $m Actual CER1 $m Actual CER - Product Sales 28,896 …

AZN1N main company

Sharemaestro market context Price below Trend Line 52 weeks -10.0% · Next-week setup negative 16.9%

10:02 27 Jul 2026

uk.finance.yahoo.com Macro sensitivity Main company 🇲🇽 Mexico

AstraZeneca sales rise as demand for cancer treatments grow

AstraZeneca has revealed that demand for its range of cancer treatments buoyed sales this year as the drugs giant increased spending on new research. The Cambridge-based company said sales growth within its oncology and rare disease divisions helped deliver a boost. It reported total …

AZN1N main company

Sharemaestro market context Price below Trend Line 52 weeks -10.0% · Next-week setup negative 16.9%

09:19 27 Jul 2026

nasdaq.com Earnings Main company 🇲🇽 Mexico

AstraZeneca Q2 Pre-tax Profit Down, But EPS Rise; Backs Positive FY26 View

(RTTNews) - British drug major AstraZeneca PLC reported Monday lower pre-tax pofit in its second quarter mainly on lower tax expenses, while earnings per share grew from last year with higher revenues, excluding weak China results. Further, the firm confirmed fiscal 2026 outlook for …

AZN1N main company

Sharemaestro market context Price below Trend Line 52 weeks -10.0% · Next-week setup negative 16.9%

08:57 27 Jul 2026

seekingalpha.com Earnings Main company 🇲🇽 Mexico

AstraZeneca PLC declares $1.06 interim dividend

* AstraZeneca PLC (AZN [https://seekingalpha.com/symbol/AZN]) declares a $1.06/share interim dividend [https://www.astrazeneca.com/media-centre/press-releases/2026/h1-and-q2-2026-results.html]. * Payable Sept. 8; for shareholders of record Aug. 7; ex-div Aug. 7. * Looking ahead for FY 2026, the company intends to increase its total annual dividend payout to $3.30 per share. …

AZN1N main company

Sharemaestro market context Price below Trend Line 52 weeks -10.0% · Next-week setup negative 16.9%

08:30 27 Jul 2026

seekingalpha.com Earnings Main company 🇲🇽 Mexico

Earnings Snapshot: AstraZeneca reports Q2 earnings beat, raises interim dividend, and reaffirms FY26 guidance

[Seeking Alpha] Seeking Alpha (Seeking Alpha) MORE ON ASTRAZENECA PLC * AstraZeneca's Oncology Engine Keeps Running Despite Wainua Setback [https://seekingalpha.com/article/4922348-astrazeneca-oncology-engine-keeps-running-despite-wainua-setback] * AstraZeneca And Ionis Pharma Rocked By Heart Disease Fail: Why You Shouldn't Panic [https://seekingalpha.com/article/4921003-astrazeneca-and-ionis-pharma-rocked-by-heart-disease-fail-why-you-shouldnt-panic] * AstraZeneca PLC (AZN) Discusses Progress in Sustainability Strategy …

AZN1N main company

Sharemaestro market context Price below Trend Line 52 weeks -10.0% · Next-week setup negative 16.9%

08:15 27 Jul 2026

seekingalpha.com Earnings Main company 🇲🇽 Mexico

AstraZeneca Q2 Non-GAAP EPS tops expectations by $1.36; reconfirms full-year outlook

* AstraZeneca PLC press release [https://www.astrazeneca.com/media-centre/press-releases/2026/h1-and-q2-2026-results.html] (AZN [https://seekingalpha.com/symbol/AZN]): Q2 Non-GAAP EPS of $2.63 beats by $1.36. * Revenue of $15.38B (+6.4% Y/Y) misses by $50M. * Interim dividend increased 3 cents to $1.06 per share (79.5 pence, 10.32 SEK). * FY2026 Revenue estimated growth …

AZN1N main company

Sharemaestro market context Price below Trend Line 52 weeks -10.0% · Next-week setup negative 16.9%

07:27 27 Jul 2026

nasdaq.com Earnings Main company 🇲🇽 Mexico

AstraZeneca Q2 Pre-tax Profit Drops, Revenues Rise; Confirms FY26 Outlook

(RTTNews) - British drug major AstraZeneca PLC (AZN, AZN.L) reported Monday lower pre-tax pofit in its second quarter, despite higher revenues. Looking ahead for fiscal 2026, AstraZeneca continues to expect total revenue to increase by a mid-to-high single-digit percentage, and core earnings per share …

AZN1N main company

Sharemaestro market context Price below Trend Line 52 weeks -10.0% · Next-week setup negative 16.9%

16:27 26 Jul 2026

nasdaq.com Earnings Main company 🇲🇽 Mexico

AstraZeneca Q2 Earnings Preview: Can Tagrisso, Imfinzi And Farxiga Sustain Momentum?

(RTTNews) - AstraZeneca PLC (AZN) is scheduled to report the second-quarter results on July 27, 2026. AstraZeneca, as a biopharmaceutical company, offers multiple products for oncology, cardiovascular, renal and metabolism, respiratory & immunology, vaccines and immune therapies, and therapies for rare diseases. AstraZeneca's blockbuster …

AZN1N main company

Sharemaestro market context Price below Trend Line 52 weeks -10.0% · Next-week setup negative 16.9%

22:11 24 Jul 2026

finance.yahoo.com Regulatory and legal Main company 🇲🇽 Mexico

AstraZeneca (LSE:AZN) Wins EU Approval For Etcamah In Advanced Breast Cancer

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. AstraZeneca received EU approval for Etcamah (camizestrant) in combination with CDK4/6 inhibitors for ER-positive, HER2-negative advanced breast cancer. The decision is based on Phase III SERENA-6 trial …

AZN1N main company

Sharemaestro market context Price below Trend Line 52 weeks -10.0% · Next-week setup negative 16.9%

16:30 24 Jul 2026

finance.yahoo.com Earnings Main company 🇲🇽 Mexico

EU Clears AZN's Etcamah Combo for First-Line ER-Positive Breast Cancer

AstraZeneca AZN announced that the European Commission (EC) has approved Etcamah (camizestrant) in combination with a CDK4/6 inhibitor for the first-line treatment of a certain type of breast cancer. The EC approved Etcamah in combination with a CDK4/6 inhibitor (palbociclib, ribociclib or abemaciclib) for …

AZN1N main company

Sharemaestro market context Price below Trend Line 52 weeks -10.0% · Next-week setup negative 16.9%

12:00 24 Jul 2026

finance.yahoo.com Earnings Main company 🇲🇽 Mexico

Enhertu® Plus Pertuzumab Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with HER2 Positive Metastatic Breast Cancer

Recommendation based on DESTINY-Breast09 phase 3 trial results that showed Enhertu plus pertuzumab reduced the risk of disease progression or death by 44% versus THP with a median progression-free survival exceeding three years If approved, Daiichi Sankyo and AstraZeneca's Enhertu plus pertuzumab would become …

AZN1N main company

Sharemaestro market context Price below Trend Line 52 weeks -10.0% · Next-week setup negative 16.9%

08:16 24 Jul 2026

finance.yahoo.com Earnings Main company 🇲🇽 Mexico

AstraZeneca (LSE:AZN) And The Valuation Case Behind Its Drug Pipeline Narrative

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. AstraZeneca (LSE:AZN) has been in focus after Illumina highlighted progress on the Billion Cell Atlas alliance. AstraZeneca is a founding member of this initiative, which uses large …

AZN1N main company

Sharemaestro market context Price below Trend Line 52 weeks -10.0% · Next-week setup negative 16.9%

07:16 24 Jul 2026

finance.yahoo.com Earnings Main company 🇲🇽 Mexico

Analysis-AstraZeneca 'magic' faces rare test after trial failure, share slide

By Maggie Fick LONDON, July 24 (Reuters) - AstraZeneca's long-time CEO Pascal Soriot has rarely put a foot wrong. The company's shares have more that quadrupled in price during his 14-year tenure, soaring above the wider FTSE 100 index and main British rival GSK. …

AZN1N main company

Sharemaestro market context Price below Trend Line 52 weeks -10.0% · Next-week setup negative 16.9%

81 matching headlines